NCT02009397View on ClinicalTrials.gov

A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Metastatic Melanoma
Interventions
DRUG

Ipilimumab

DRUG

GM-CSF

Trial Locations (1)

40202

James Graham Brown Cancer Center, Louisville

All Listed Sponsors
collaborator

James Graham Brown Cancer Center

OTHER

lead

University of Louisville

OTHER

NCT02009397 - A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients | Biotech Hunter | Biotech Hunter